← All trials
NCT07239115
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2026
- Primary completion
- Jan 31, 2027
- Completion date
- Jun 30, 2027
- First posted
- Nov 20, 2025
- Last posted
- Nov 20, 2025
- Enrollment
- 558
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversityOfficial
- Capital Medical UniversitySponsor investigator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.